Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
Abstract A combination of olanzapine and samidorphan (OLZ/SAM) was recently approved by the US Food and Drug Administration for treatment of patients with schizophrenia or bipolar I disorder. The effects of moderate hepatic impairment on the pharmacokinetics (PKs) of olanzapine and samidorphan after...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2021-09-01
|
| Col·lecció: | CPT: Pharmacometrics & Systems Pharmacology |
| Accés en línia: | https://doi.org/10.1002/psp4.12675 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|